Á¦9ȸ ´ëÇѰǼ±ÇÐȸ »ý¹°ÇÐÀûÁ¦Á¦ ½ÉÆ÷Áö¾ö : 2021-12-11±³À°ÀÏÀÚ : 2021-12-11
±³À°Àå¼Ò : »ïÁ¤È£ÅÚ ¶óº¥´õȦ
±³À°ÁÖÁ¦ :
Á¦9ȸ ´ëÇѰǼ±ÇÐȸ »ý¹°ÇÐÀûÁ¦Á¦ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѰǼ±ÇÐȸ
´ã´çÀÚ : ±èµ¿Çö ±³¼ö
¿¬¶ôó : 031-780-1839
À̸ÞÀÏ :
terios92@cha.ac.kr ±³À°Á¾·ù : ÇǺΰú
Âü¼®¿¹»óÀοø : 70¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-11 ¶óº¥´õȦ 13:00~13:30 Guidelines/best practice for psoriasis ¹ÚÀºÁÖ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 12-11 ¶óº¥´õȦ 13:30~14:00 Guidelines/best practice for psoriatic arthritis ±èÁ¤Àº(ÇѾçÀÇ´ë)
Åä·Ð 12-11 ¶óº¥´õȦ 14:00~14:10 Q&A ¹ÚÀºÁÖ, ±èÁ¤Àº(ÇѸ²ÀÇ´ë, ÇѾçÀÇ´ë)
±³À°½Ã°£ 12-11 ¶óº¥´õȦ 14:10~14:40 Drug survival º¯Áö¿¬(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 12-11 ¶óº¥´õȦ 14:40~15:10 Immunogenicity ±èűÕ(¿¬¼¼ÀÇ´ë)
Åä·Ð 12-11 ¶óº¥´õȦ 15:10~15:20 Q&A º¯Áö¿¬, ±èűÕ(ÀÌÈÀÇ´ë, ¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 12-11 15:20~15:40 ()
±³À°½Ã°£ 12-11 ¶óº¥´õȦ 15:40~16:05 Availability of many alternatives, High costs ¹æöȯ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 12-11 ¶óº¥´õȦ 16:05~16:30 Benefit of early intervention ÃÖÀ¯¼º(¿ï»êÀÇ´ë)
±³À°½Ã°£ 12-11 ¶óº¥´õȦ 16:30~16:55 Sensitive locations like the scalp, palms, or genitals Á¤±âÇå(°æÈñÀÇ´ë)
Åä·Ð 12-11 ¶óº¥´õȦ 16:55~17:20 Debate ¹æöȯ, ÃÖÀ¯¼º, Á¤±âÇå(°¡Å縯ÀÇ´ë, ¿ï»êÀÇ´ë, °æÈñÀÇ´ë)